- Home
- OLMA vs KOD Comparison
OLMA vs KOD Comparison
Compare OLMA & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- KOD
- Stock Information
- Founded
- OLMA 2006
- KOD 2009
- Country
- OLMA United States
- KOD United States
- Employees
- OLMA N/A
- KOD N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OLMA Health Care
- KOD Health Care
- Exchange
- OLMA Nasdaq
- KOD Nasdaq
- Market Cap
- OLMA 420.2M
- KOD 454.7M
- IPO Year
- OLMA 2020
- KOD 2018
- Fundamental
- Price
- OLMA $5.66
- KOD $7.17
- Analyst Decision
- OLMA Strong Buy
- KOD Hold
- Analyst Count
- OLMA 5
- KOD 4
- Target Price
- OLMA $26.25
- KOD $8.00
- AVG Volume (30 Days)
- OLMA 1.3M
- KOD 464.9K
- Earning Date
- OLMA 03-10-2025
- KOD 11-14-2024
- Dividend Yield
- OLMA N/A
- KOD N/A
- EPS Growth
- OLMA N/A
- KOD N/A
- EPS
- OLMA N/A
- KOD N/A
- Revenue
- OLMA N/A
- KOD N/A
- Revenue This Year
- OLMA N/A
- KOD N/A
- Revenue Next Year
- OLMA N/A
- KOD N/A
- P/E Ratio
- OLMA N/A
- KOD N/A
- Revenue Growth
- OLMA N/A
- KOD N/A
- 52 Week Low
- OLMA $4.60
- KOD $2.19
- 52 Week High
- OLMA $16.78
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- OLMA 41.95
- KOD 42.02
- Support Level
- OLMA $4.60
- KOD $7.21
- Resistance Level
- OLMA $5.83
- KOD $9.14
- Average True Range (ATR)
- OLMA 0.54
- KOD 0.89
- MACD
- OLMA 0.15
- KOD -0.35
- Stochastic Oscillator
- OLMA 59.55
- KOD 0.27
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.